Ocular Behçet disease: Current therapeutic approaches

Current Opinion in Ophthalmology

Volumn 22, Issue 6, 2011, Pages 508-516

  Evereklioglu, Cem ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

biological therapy; infliximab; ocular Beh et disease; treatment; tumor necrosis factor blockers

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETAMETHASONE; CHLORAMBUCIL; COLCHICINE; CYCLOPENTOLATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DICLOFENAC; FLURBIPROFEN; HYDROCORTISONE; INDOMETACIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; PHENYLEPHRINE; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; RITUXIMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TROPICAMIDE;

ABDOMINAL DISCOMFORT; ACNE; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; AZOOSPERMIA; BEHCET DISEASE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BREAST TENDERNESS; BRONCHOSPASM; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; COUGHING; CREATININE BLOOD LEVEL; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DYSPNEA; EYE DISCOMFORT; EYE INFLAMMATION; EYE PAIN; FERTILITY; FEVER; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GOITER; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HIRSUTISM; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOTENSION; IRIDOCYCLITIS; JAUNDICE; KIDNEY DISEASE; LEG CRAMP; LEUKOPENIA; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; MENTAL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OCULAR BEHCET DISEASE; PANCREATITIS; PARESTHESIA; PERFORATING EYE INJURY; PHOTOPHOBIA; PNEUMONIA; PRIORITY JOURNAL; PTOSIS; RASH; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; RETINOPATHY; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREMOR; TUBERCULOSIS; URTICARIA; UVEITIS; VERTIGO; VOMITING; XEROSTOMIA;

BEHCET SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRIDOCYCLITIS; PANUVEITIS;

EID: 80054897022     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834bbe91     Document Type: Article

References (62)

1. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005; 50:297-350. (Pubitemid 40828225)
2. Borlu M, Ukşal Ü, Ferahbaş A, Evereklioglu C. Clinical features of Behçet's disease in children. Int J Dermatol 2006; 45:713-716. (Pubitemid 44056675)
3. Evereklioglu C, Türköz Y, Er H, et al. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46:50-54. (Pubitemid 34073477)
4. Evereklioglu C, Inalöz HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. Br J Dermatol 2002; 147:331-336.
5. Evereklioglu C, Çekmen M, O ̈zkiriş A, et al. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behçet's disease. Mediators Inflamm 2003; 12:255-256. (Pubitemid 37297196)
6. Evereklioglu C, O ̈zbek E, Çekmen M, et al. Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behçet's disease: is it a new urinary activity marker? Nephrology 2003; 8:246-253.
7. Çekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol 2003;42:870-875.
8. Türköz Y, Evereklioglu C,O ̈zkiriş A, et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behçet's syndrome. Mediators Inflamm 2005;4:237-241. (Pubitemid 41381516)
9. Evereklioglu C, Yürekli M, Er H, et al. Increased plasma adrenomedullin levels in patients with Behçet's disease. Dermatology 2000; 201:312-315. (Pubitemid 32037557)
10. Evereklioglu C, O ̈zbek E, Er H, et al. Urinary adrenomedullin levels are increased and correlated with plasma concentrations in patients with Behçet's syndrome. Int J Urol 2002; 9:296-303. (Pubitemid 34779712)
11. Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002; 86:653-657. (Pubitemid 34627956)
12. Erkiliç K, Evereklioglu C, Çekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease. Mediators Inflamm 2003; 12:107-116. (Pubitemid 36783250)
13. Özkul Y, Evereklioglu C, Borlu M, et al. The 5,10- methylenetetrahydrofolate reductase C677T gene polymorphism in Behçet's patients with or without ocular involvement. Br J Ophthalmol 2005;89:1634-1637.
14. Borlu M, Cölgeçen E, Evereklioglu C. Behçet's disease and vitiligo in two brothers: coincidence or association? Clin Exp Dermatol 2009; 34:653-655.
15. Inalöz HS, Evereklioglu C, Ünal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome. J Eur Acad Dermatol Venereol 2004;18:56-61.
16. Günen H, Evereklioglu C, Koşar F, et al. Thoracic involvement in Behçet's disease and its correlation with multiple parameters. Lung 2000; 178:161-170. (Pubitemid 30489904)
17. Evereklioglu C, Çokkeser Y, Doganay S, et al. Audio-vestibular evaluation in patients with Behçet's syndrome. J Laryngol Otol 2001; 115:704-708. (Pubitemid 32896919)
18. Evereklioglu C, Er H. Increased corneal thickness in active Behçet's disease. Eur J Ophthalmol 2002; 12:24-29. (Pubitemid 34245818)
19. Karlidag R, Ünal S, Evereklioglu C, et al. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17:670-675. (Pubitemid 37428089)
20. Bayazit YA, Evereklioglu C, O ̈zer E, et al. Neurotologic status in Behçet's disease anditsophthalmologic correlates.PostgradMed J2004;80:724-728. (Pubitemid 39627106)
21. Duygulu F, Evereklioglu C, Ç aliş M, et al. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet's disease. Clin Rheumatol 2005; 24:324-330. (Pubitemid 41102427)
22. Behçet H. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. Dermatol Wochenschr 1937; 105:1152-1157.
23. Evereklioglu C. Diagnostic dilemma between intestinal Behçet disease and inflammatory bowel disease with pyoderma gangrenosum. World J Gastroenterol 2006; 12:5748-5751. (Pubitemid 44594059)
24. Evereklioglu C. Regarding the naming dilemma of Behçet disease in the 21st century. Oral Dis 2007; 13:117-121. (Pubitemid 46046546)
25. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-1080.
26. The Behçet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease: a multicenter study. J Rheumatol 1989; 16:506-511.
27. Evereklioglu C. The migration pattern, patient selection with diagnostic methodological flaw and confusing naming dilemma in Behçet disease. Eur J Echocardiogr 2007; 143:328-333.
28. Evereklioglu C. Behçet's disease or Adamantiades-Behçet disease? An evidence-based historical survey. Med Sci Monit 2010; 16:136-142.
29. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother 2004; 5:317-328.
30. Evereklioglu C, Er H, Türköz Y, Çekmen M. Serum levels of TNF-a, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11:87-93. (Pubitemid 34526411)
31. Evereklioglu C, Borlu M. Sustained remission after infliximab in a child with systemic vasculitis refractory to conventional immunosuppressive therapy including interferon-a. Br J Ophthalmol 2008; 92:1034; Education 1148-1149.
32. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007; 51:191-196. (Pubitemid 46889493)
33. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol 2011; 95:205-208.
34. Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int 2008; 29:53-57.
35. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008; 146:845-850.
36. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010; 94:284-288.
37. Tanaka H, Sugita S, Yamada Y, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease. Nippon Ganka Gakkai Zasshi 2010; 114:87-95.
38. Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol 2010; 30:577-581.
39. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31:33-37.
40. Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology (Oxford) 2011; 50:593-597.
41. Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken) 2010; 62:1733.
42. Kawaguchi T, Sugita S, Yamada Y, et al. Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 2010; 26:627-630.
43. Van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007; 66:565-566. (Pubitemid 46580490)
44. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sightthreatening uveitis in Behçet's disease. Eye 2007; 21:824-825. (Pubitemid 46909189)
45. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2011; 31:243-245.
46. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010; 18:226-232.
47. Atmaca LS, Yalçindag? FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007; 245:451-456. (Pubitemid 46404010)
48. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007; 23:395-401. (Pubitemid 350195065)
49. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-a 2b for refractory ocular Behçet's disease. Lancet 1994; 343:1428. (Pubitemid 24167522)
50. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-a 2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33:311-319. (Pubitemid 38496040)
51. Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr Opin Ophthalmol 2006; 17:567-573. (Pubitemid 44655592)
52. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon- alpha in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford) 2007; 46:1570-1573. (Pubitemid 47500572)
53. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 2010; 117:1430-1435.
54. Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 2010; 62:2796-2805.
55. Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 2011; 129:288-294.
56. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 2008; 18: 306-308.
57. Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13:246-252.
58. Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007; 41:449-454.
59. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010; 224:46-53.
60. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116:797-801.
61. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30:1530-1535.
62. Chams-Davatchi C, Bribin B, Shahram F, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behçet's disease: a randomized double-blind controlled trial. Int J Rheum Dis 2010; 13:253-258.